Search research articles
Contact Us
Filters
Showing results (251-260 of 265) with videos related to
Page
of 27
Sort By:
Cardiovascular Research
|
October 22, 2025
A multi-omics approach uncovers causality of IL6R on endotypes of subclinical carotid atherosclerosis and the possible role of the IL6R/OSMR pathway
Qiao Sen Chen, Hanna M Björck, Otto Bergman, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
August 15, 2022
Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
Peter E Penson, Eric Bruckert, David Marais, et al.
Atherosclerosis
|
August 31, 2020
Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study
Nicola Ferri, Massimiliano Ruscica, Daniela Coggi, et al.
Biomedicines
|
April 3, 2021
The Association between HDL-C and Subclinical Atherosclerosis Depends on CETP Plasma Concentration: Insights from the IMPROVE Study
Gualtiero I Colombo, Vanessa Bianconi, Alice Bonomi, et al.
Open Heart
|
October 10, 2025
<i><b>PCSK9</b></i> <b>genetic variants, carotid atherosclerosis and vascular remodelling</b>
Daniela Coggi, Joey Ward, Chiara Macchi, et al.
Biomedicines
|
August 6, 2021
Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study
Daniela Coggi, Beatrice Frigerio, Alice Bonomi, et al.
Giornale Italiano Di Cardiologia (2006)
|
September 28, 2023
[How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy]
Marcello Arca, Maurizio Averna, Claudio Borghi, et al.
Giornale Italiano Di Cardiologia (2006)
|
March 24, 2020
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts]
Maddalena Lettino, Alberto Zambon, Giuseppe Musumeci, et al.
Scientific Reports
|
January 13, 2021
The overlap of genetic susceptibility to schizophrenia and cardiometabolic disease can be used to identify metabolically different groups of individuals
Rona J Strawbridge, Keira J A Johnston, Mark E S Bailey, et al.
The Journal of Clinical Investigation
|
October 2, 2015
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII
Davide Matino, Marco Gargaro, Elena Santagostino, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 265) with videos related to
Sort By:
Page
of 27
Cardiovascular Research
|
October 22, 2025
A multi-omics approach uncovers causality of IL6R on endotypes of subclinical carotid atherosclerosis and the possible role of the IL6R/OSMR pathway
Qiao Sen Chen, Hanna M Björck, Otto Bergman, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
August 15, 2022
Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
Peter E Penson, Eric Bruckert, David Marais, et al.
Atherosclerosis
|
August 31, 2020
Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study
Nicola Ferri, Massimiliano Ruscica, Daniela Coggi, et al.
Biomedicines
|
April 3, 2021
The Association between HDL-C and Subclinical Atherosclerosis Depends on CETP Plasma Concentration: Insights from the IMPROVE Study
Gualtiero I Colombo, Vanessa Bianconi, Alice Bonomi, et al.
Open Heart
|
October 10, 2025
<i><b>PCSK9</b></i> <b>genetic variants, carotid atherosclerosis and vascular remodelling</b>
Daniela Coggi, Joey Ward, Chiara Macchi, et al.
Biomedicines
|
August 6, 2021
Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study
Daniela Coggi, Beatrice Frigerio, Alice Bonomi, et al.
Giornale Italiano Di Cardiologia (2006)
|
September 28, 2023
[How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy]
Marcello Arca, Maurizio Averna, Claudio Borghi, et al.
Giornale Italiano Di Cardiologia (2006)
|
March 24, 2020
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts]
Maddalena Lettino, Alberto Zambon, Giuseppe Musumeci, et al.
Scientific Reports
|
January 13, 2021
The overlap of genetic susceptibility to schizophrenia and cardiometabolic disease can be used to identify metabolically different groups of individuals
Rona J Strawbridge, Keira J A Johnston, Mark E S Bailey, et al.
The Journal of Clinical Investigation
|
October 2, 2015
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII
Davide Matino, Marco Gargaro, Elena Santagostino, et al.
Page
of 27